An efficient strategy for the para-selective borylation of aromatic esters is described. For achieving high para-selectivity, a new catalytic system has been developed modifying the core structure of the bipyridine. It has been proposed that the L-shaped ligand is essential to recognize the functionality of the oxygen atom of the ester carbonyl group via noncovalent interaction, which provides an unprecedented
The Synthesis of Biarylmonophosphonates via Palladium-Catalyzed Phosphonation, Iridium-Catalyzed C-H Borylation, Palladium-Catalyzed Suzuki–Miyaura Cross-Coupling
作者:Simon Doherty、Julian G. Knight、Tina S. T. Tran、Hussam Y. Alharbi、Daniel O. Perry
DOI:10.1007/s10562-021-03643-3
日期:2022.2
arylboronic esters as the sole product; the resulting boronic esters were used as nucleophilic reagents in a subsequent palladium-catalyzed Suzuki–Miyauracross-coupling to generate a range of biarylmonophosphonates. Gratifyingly, the Suzuki–Miyauracross-coupling can be conducted without purifying the boronic ester which greatly simplifies the synthetic procedure. Graphical Abstract
Potent Reductants via Electron-Primed Photoredox Catalysis: Unlocking Aryl Chlorides for Radical Coupling
作者:Nicholas G. W. Cowper、Colleen P. Chernowsky、Oliver P. Williams、Zachary K. Wickens
DOI:10.1021/jacs.9b12328
日期:2020.2.5
productively engage aryl chlorides with reduction potentials hundreds of millivolts beyond the potential of Na0 in productive radical coupling reactions. The arylradicals produced via this strategy can be leveraged for both carbon-carbon and carbon-heteroatom bond-forming reactions. Through direct comparison, we illustrate the reactivity and selectivity advantages of this approach relative to electrolysis
[EN] IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER<br/>[FR] DÉRIVÉS D'IMIDAZO [1,2-C]PYRIMIDINE UTILISÉS COMME INHIBITEURS DE PRC2 POUR LE TRAITEMENT DU CANCER
申请人:MIRATI THERAPEUTICS INC
公开号:WO2020247475A1
公开(公告)日:2020-12-10
Disclosed are compounds that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, disclosed are compounds of Formula (I) and pharmaceutical compositions thereof, and methods of using the compounds and pharmaceutical compositions in, for example, methods of treating cancer.
[EN] NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS<br/>[FR] DÉRIVÉS DE NAPHTYRIDINE EN TANT QU'INHIBITEURS DE PRC2
申请人:MIRATI THERAPEUTICS INC
公开号:WO2020219448A1
公开(公告)日:2020-10-29
Disclosed are compounds of formula (I) or (II) that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.